MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2024 International Congress

    The potential role of monocytes a-synuclein and lipids as predictors of PD.

    S. Lucas-Del-Pozo, G. Uras, D. Moreno-Martinez, F. Fierli, S. Koletsi, C. Manis, P. Caboni, D. Hughes, A. Schapira (London, United Kingdom)

    Objective: To study the role monocytic A-syn and lipids as biomarkers of PD. Background: A chronic pro-inflammatory pattern is present in Parkinson’s disease (PD) patients’…
  • 2024 International Congress

    Path To Prevention (P2P) Therapeutics Platform Trial in Stage 2B Neuronal Alpha-Synuclein Disease: Study Update

    T. Simuni, C. Coffey, A. Siderowf, C. Tanner, S. Chowdhury, T. Sherer, C. Kopil, K. Kieburtz, B. Saville, C. Allen-Savietta, B. Wendelberger, A. Crawford, K. Fabrizio, K. Marek (Chicago, USA)

    Objective: To describe the study design and timeline of the first interventional study in  Neuronal α-Synuclein Disease (NSD). Background: P2P is a platform, Phase 2…
  • 2024 International Congress

    Baseline NSD-ISS stage predicts long term progression and survival in sporadic PD: 10-year PPMI data analysis

    P. Gonzalez-Latapi, C. Gochanour, H. Cho, S. Ho Choi, C. Caspell, C. Coffey, M. Brumm, Y. Xiao, DE. Lafontant, C. Venuto, C. Tanner, K. Kieburtz, L. Chahine, A. Siderowf, K. Marek, T. Simuni (Chicago, USA)

    Objective: To analyze long term progression in Neuronal Synuclein Disease (NSD) participants who were originally enrolled in the sporadic Parkinson Disease (sPD) cohort in PPMI…
  • 2024 International Congress

    Chronic Sleep Fragmentation Accelerates the Onset of Prodromal Symptoms and Pathology in Parkinson’s Disease Model Mice

    M. Miyazaki, H. Yagihara, H. Fujita, H. Yamakado, K. Wada, E. Minakawa (Kodaira, Japan)

    Objective: To investigate whether chronic sleep fragmentation accelerates the onset of prodromal symptoms and pathology of Parkinson’s disease (PD) in mice. Background: The prodromal phase…
  • 2024 International Congress

    IGF2 Induce Neuroprotection in PD Preclinical Models by Modulation of Immune Response.

    FG. Grünenwald, MC. Cisternas, DS. Sepulveda, TH. Huerta, CJ. Jerez, RP. Pacheco, RLV. Vidal (Santiago, Chile)

    Objective: We propose to determine a therapeutic strategy based on adoptive transfer of macrophages reprogrammed for recombinant IGF2 (rIGF2) treatment in PD preclinical model. Background:…
  • 2024 International Congress

    Hyposmia is Associated with Positive CSF α-Synuclein Seeding in Normal Pressure Hydrocephalus

    S. Weber, C. Farris, Y. Ma, M. Dakna, M. Starke, C. Trenkwalder, L. Concha-Marambio, B. Mollenhauer (Goettingen, Germany)

    Objective: To detect α-synuclein (αSyn) pathology and associated clinical characteristics in patients with idiopathic normal pressure hydrocephalus (iNPH) through cerebrospinal fluid (CSF) αSyn seed amplification…
  • 2024 International Congress

    α-Synuclein Seed Amplification Assay Amplification Parameters and Progression in Parkinson’s Disease

    D. Coughlin, B. Shifflett, A. Siderowf, S. Edland, D. Galasko, C. Farris, Y. Ma, C. Soto, L. Concha-Marambio (San Diego, USA)

    Objective: To examine the relationship between the reaction parameters of the cerebrospinal fluid (CSF) αSyn seed amplification assay (αSyn-SAA) to the risk of developing motor…
  • 2024 International Congress

    Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson’s Consortium

    D. Stephenson, C. Kopil, M. Müller, O. Mabrouk, H. Kocherla, R. Comley, K. Yee, T. Dam, G. Pagano, J. Seibyl, K. Marek, T. Simuni (Tucson, USA)

    Objective: To advance the regulatory maturity of drug development tools to support the newly proposed integrated staging of Neuronal Synuclein Disease (NSD-ISS) with focus on…
  • 2024 International Congress

    Understanding the neuroprotective mechanism of ilex Paraguariensis (Yerba mate) in a Drosophila melanogaster alpha-synuclein model of Parkinson’s disease

    A. Tschopp, P. Ballestero, G. Decurgez, H. Hauche, T. Eidelman, M. Bordone, N. Muraro, J. Ferrario (CABA, Argentina)

    Objective: To investigate behavioral and cellular changes in the brain of a Drosophila melanogaster model of Parkinson’s Disease (PD) exposed to yerba mate [YM] extract.…
  • 2024 International Congress

    Development of an AAV-mediated artificial miRNA targeting human alpha-synuclein (α-syn) as a potential gene therapy for Synucleinopathies

    S. Basu, V. Singh, N. Gattone, J. Li, B. Wicks, X. Huang, E. Fabyanic, S. Wang, M. Li, X. Qian, G. Rivera-Pena, C. Li, Z. Yu, P. Raman, E. Kostuk, MG. Biferi, E. Ramsburg (Philadelphia, USA)

    Objective: To develop an adeno-associated virus (AAV)-based artificial miRNA (miRNA) system targeting human α-syn. Background: Synucleinopathies such as Parkinson’s disease (PD) and Multiple System Atrophy…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 60
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley